bs-12014R-PE [Conjugated Primary Antibody]
MGLUR1 + MGLUR5 Polyclonal Antibody, PE Conjugated
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Rabbit

Target Protein: MGLUR1 + MGLUR5

Immunogen Range: 501-600/1194


Clonality: Polyclonal

Isotype: IgG

Source: KLH conjugated synthetic peptide derived from human MGLUR1 + MGLUR5

Purification: Purified by Protein A.

Storage Buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Background:

Glutamate is the main excitatory neurotransmitter in the brain. For many years it had been considered to act only on the ligand-gated receptor channels-termed NMDA, AMPA and kainite receptors that are involved in the fast excitatory synaptic transmission. Recently, glutamate has been shown to regulate enzymes producing second messengers via specific receptors coupled to G-proteins. These receptors are called metabotropic glutamate receptors. In expression systems, Group-I receptors stimulate phospholipase C as revealed by an increase in phosphoinositide turnover and calcium release from internal stores. Group-II and -III receptors are coupled to the inhibition of adenylyl cyclase. The Group-I receptors include Metabotropic Glutamate Receptor 5 and Metabotropic Glutamate Receptor 1a. The Group-II receptors in include mGluR2 and mGluR3.

Conjugation: PE

Excitation/ Emission: 496,564nm/578nm

Size: 100ul

Concentration: 1ug/ul

Applications: WB(1:300-5000)

Predicted Molecular Weight: 130


Cross Reactive Species: Mouse

Predicted Cross Reactive Species: Human
Rat
Dog
Cow
Sheep
Pig
Horse
Chicken

For research use only. Not intended for diagnostic or therapeutic use.

PRODUCT SPECIFIC PUBLICATIONS
  • X Zhou et al. Modulating NMDA receptors to treat MK-801-induced schizophrenic cognition deficit: effects of clozapine combining with PQQ treatment and possible mechanisms of action. BMC Psychiatry. 2020 Mar 6;20(1):106.Read more>>
VALIDATION IMAGES